W Oliver Tobin1, Alicja Kalinowska-Lyszczarz1, Stephen D Weigand1, Yong Guo1, Nirubol Tosakulwong1, Joseph E Parisi1, Imke Metz1, Josa M Frischer1, Hans Lassmann1, Wolfgang Brück1, Linda Linbo1, Claudia F Lucchinetti2. 1. From the Department of Neurology (W.O.T., Y.G., L.L.), Health Sciences Research (S.D.W., N.T.), and Department of Pathology (J.E.P.), Mayo Clinic, Rochester, MN; Poznan University of Medical Sciences (A.K.-L.), Poland; University of Göttingen (I.M., W.B.), Germany; Medical University of Vienna (J.M.F., H.L.), Austria; and Departments of Neurosciences (C.F.L.), Neurology (C.F.L.), and Clinical and Translational Science (C.F.L.), Mayo Clinic, College of Medicine, Rochester, MN. 2. From the Department of Neurology (W.O.T., Y.G., L.L.), Health Sciences Research (S.D.W., N.T.), and Department of Pathology (J.E.P.), Mayo Clinic, Rochester, MN; Poznan University of Medical Sciences (A.K.-L.), Poland; University of Göttingen (I.M., W.B.), Germany; Medical University of Vienna (J.M.F., H.L.), Austria; and Departments of Neurosciences (C.F.L.), Neurology (C.F.L.), and Clinical and Translational Science (C.F.L.), Mayo Clinic, College of Medicine, Rochester, MN. clucchinetti@mayo.edu.
Abstract
BACKGROUND AND OBJECTIVES: The goal of this work was to compare clinical characteristics across immunopathologic subtypes of patients with multiple sclerosis. METHODS: Immunopathologic subtyping was performed on specimens from 547 patients with biopsy- or autopsy-confirmed CNS demyelination. RESULTS: The frequency of immunopathologic subtypes was 23% for pattern I, 56% for pattern II, and 22% for pattern III. Immunopatterns were similar in terms of age at autopsy/biopsy (median age 41 years, range 4-83 years, p = 0.16) and proportion female (54%, p = 0.71). Median follow-up after symptom onset was 2.3 years (range 0-38 years). In addition to being overrepresented among autopsy cases (45% vs 19% in biopsy cohort, p < 0.001), index attack-related disability was higher in pattern III vs II (median Expanded Disability Status Scale score 4 vs 3, p = 0.02). Monophasic clinical course was more common in patients with pattern III than pattern I or II (59% vs 33% vs 32%, p < 0.001). Similarly, patients with pattern III pathology were likely to have progressive disease compared to patients with patterns I or II when followed up for ≥5 years (24% overall, p = 0.49), with no differences in long-term survival, despite a more fulminant attack presentation. CONCLUSION: All 3 immunopatterns can be detected in active lesions, although they are found less frequently later into the disease due to the lower number of active lesions. Pattern III is associated with a more fulminant initial attack than either pattern I or II. Biopsied patients appear to have similar long-term outcomes regardless of their immunopatterns. Progressive disease is less associated with the initial immunopattern and suggests convergence into a final common pathway related to the chronically denuded axon.
BACKGROUND AND OBJECTIVES: The goal of this work was to compare clinical characteristics across immunopathologic subtypes of patients with multiple sclerosis. METHODS: Immunopathologic subtyping was performed on specimens from 547 patients with biopsy- or autopsy-confirmed CNS demyelination. RESULTS: The frequency of immunopathologic subtypes was 23% for pattern I, 56% for pattern II, and 22% for pattern III. Immunopatterns were similar in terms of age at autopsy/biopsy (median age 41 years, range 4-83 years, p = 0.16) and proportion female (54%, p = 0.71). Median follow-up after symptom onset was 2.3 years (range 0-38 years). In addition to being overrepresented among autopsy cases (45% vs 19% in biopsy cohort, p < 0.001), index attack-related disability was higher in pattern III vs II (median Expanded Disability Status Scale score 4 vs 3, p = 0.02). Monophasic clinical course was more common in patients with pattern III than pattern I or II (59% vs 33% vs 32%, p < 0.001). Similarly, patients with pattern III pathology were likely to have progressive disease compared to patients with patterns I or II when followed up for ≥5 years (24% overall, p = 0.49), with no differences in long-term survival, despite a more fulminant attack presentation. CONCLUSION: All 3 immunopatterns can be detected in active lesions, although they are found less frequently later into the disease due to the lower number of active lesions. Pattern III is associated with a more fulminant initial attack than either pattern I or II. Biopsied patients appear to have similar long-term outcomes regardless of their immunopatterns. Progressive disease is less associated with the initial immunopattern and suggests convergence into a final common pathway related to the chronically denuded axon.
Authors: N Abou Zeid; I Pirko; B Erickson; S D Weigand; K M Thomsen; B Scheithauer; J E Parisi; C Giannini; L Linbo; C F Lucchinetti Journal: Neurology Date: 2012-05-09 Impact factor: 9.910
Authors: Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker Journal: Neurology Date: 2015-06-19 Impact factor: 9.910
Authors: Mylyne Tham; Josa M Frischer; Stephen D Weigand; Patrick D Fitz-Gibbon; Samuel M Webb; Yong Guo; Reginald C Adiele; Christopher A Robinson; Wolfgang Brück; Hans Lassmann; Kendra L Furber; M Jake Pushie; Joseph E Parisi; Claudia F Lucchinetti; Bogdan F Popescu Journal: Ann Neurol Date: 2020-12-19 Impact factor: 10.422
Authors: Mahboubeh Fereidan-Esfahani; Paul A Decker; Jeanette E Eckel Passow; Claudia F Lucchinetti; Eoin Patrick Flanagan; William Oliver Tobin Journal: Eur J Neurol Date: 2021-12-09 Impact factor: 6.089
Authors: Peter A Maple; Alberto Ascherio; Jeffrey I Cohen; Gary Cutter; Gavin Giovannoni; Claire Shannon-Lowe; Radu Tanasescu; Bruno Gran Journal: Front Neurol Date: 2022-06-24 Impact factor: 4.086
Authors: Patrick Vanderdonckt; Francesca Aloisi; Giancarlo Comi; Alexander de Bruyn; Hans-Peter Hartung; Inge Huitinga; Tanja Kuhlmann; Claudia F Lucchinetti; Imke Metz; Richard Reynolds; Hans Lassmann Journal: Brain Commun Date: 2022-04-19